Novartis AG CEO Vas Narasimhan laid out the company's near- and long-term growth plans to investors, committing to delivering compound annual growth (CAGR) of 4% through 2026 despite the anticipated loss of several top-selling brands to generic competition. The company presented its growth strategy and the key brands and pipeline assets that will drive that growth during a five-hour R&D day on 2 December.
"From 2020 to 2026, the Novartis story is driven by six major brands and then some additional pipeline launches, where...








